SureTrader SureTrader
Home > Boards > US OTC > Miscellaneous >

Vitality Biopharma Inc. (VBIO)

VBIO RSS Feed
Add VBIO Price Alert      Hide Sticky   Hide Intro
Moderator: Dadx4
Search This Board:
Last Post: 1/15/2017 4:11:27 PM - Followers: 58 - Board type: Free - Posts Today: 0

 

 

Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders. We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as multiple sclerosis.  We aim to go beyond providing symptomatic relief to patients afflicted with these disorders, such as treatment of muscle spasticity in multiple sclerosis, and to instead identify combination treatments that treat the underlying cause of disease and hold the potential to help patients recover lost function.

Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, the prodrug may be approved rapidly through demonstrating similar bioavailability or bioequivalence, and at the same time a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid.  As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.

One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 30 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.




Cannabosides – A New Class of Cannabinoid Pharmaceuticals

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.

Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.

In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.


 

Cannabosides – A Novel Class of Cannabinoid Prodrugs
Novel cannabinoid glycoside compositions of matter have reliably lead to dramatic improvements in drug solubility and stability, as evidenced below.
Patents are pending for more than 20 novel cannabinoid glycoside prodrugs (including prodrug versions of of CBD, THC, CBDV, and more).
As federal restrictions on medical research in this field are beginning to relax, and as interest from the public continues to mount, there is a striking increase in the number of clinical trials being sponsored by academic investigators for use of cannabinoids to treat lucrative, large market disease indications.  Given our ability to rapidly create proprietary prodrug versions of each these cannabinoids, we stand to benefit from emerging data, and increasing recognition from the medical community of the potent pain relief and anti-inflammatory effects of cannabinoids.

Studies have shown that cannabinoids can be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects.  Specifically, cannabinoid drugs can be nearly 10 times as potent as opiates for pain relief, including morphine.  Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation.





 

Our compounds take advantage of a targeted-release mechanism where microbial enzymes present in the intestines will enable a very site-specific localized release of compounds including THC, CBD, and many of the other known cannabinoids. Because of this, we could provide targeted relief of inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis, simply by enabling larger doses of cannabinoids to be delivered.

click photo to view presentation

 

Through extensive research in the natural sweetener industry, we pioneered industrial-scale processes to modify stevia to make it taste better. This process is known as glycosylation, which involves adding additional glucose molecules to it, and it modifies both the taste and solubility of it. Over the last 10 years or so, it has become appreciated within the pharmaceutical industry that glycosylation could act to generate new natural product libraries with improved drug properties. This process for modifying natural products to make them more useful is often called glycorandomization, or glycodiversification.

Using the same technology, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel cannabinoid prodrug pharmaceuticals. As an example, one of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has potential therapeutic effects in a wide variety of serious neurological and inflammatory conditions. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as site-specific delivery that avoids or reduces psychoactivity, a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that could enable long-lasting, overnight relief.

Vitality has filed intellectual property applications including strong composition of matter claims for prodrugs of THC, CBD, and CBDV, creating proprietary prodrugs of every significant cannabinoid pharmaceutical available today.





Company News & Media
 

Press Releases

 
Sep 13, 2016 Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications Press Release
Sep 12, 2016 Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference Press Release
Aug 24, 2016 Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio Press Release
Aug 17, 2016 Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO" Press Release
Jul 27, 2016 Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease Press Release
Jul 19, 2016 Vitality Biopharma Name Change and Corporate Actions Receive Shareholder Approval Press Release
Jun 1, 2016 Vitality Biopharma to Present at LD Micro and BIO Conferences Press Release
May 9, 2016 Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development Press Release
Sep 3, 2015 Stevia First Corp. to Present at Rodman & Renshaw 17th Annual Global Investment Conference Press Release
Aug 25, 2015 Stevia First Corp. Launches Campaign to Divorce Sports World From Sugary Beverages Press Release
 

CEO Blog

What We Should Know About Opiates and Prescription Drug Abuse September 8, 2016
Magnifying the Therapeutic Effects of Medical Marijuana through Targeted Delivery August 9, 2016
Our Company Turns Towards Drug Development and Cannabinoid Pharmaceuticals July 19, 2016
 

In the News


 

 





 

Company Info

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VBIO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#1291   There is definitely a lot more positive spin superchg2 01/15/17 04:11:27 PM
#1290   *heard* dstrader 01/13/17 10:07:22 AM
#1289   Vitality Biopharma, Inc. dstrader 01/13/17 10:06:23 AM
#1288   I feel like this stock isn't getting it's dstrader 01/13/17 09:59:20 AM
#1285   all in on pivot to $4+ again myop $$$ kingsransome 01/09/17 10:24:51 AM
#1284   $VBIO http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:news simmons420 01/09/17 09:13:36 AM
#1283   2.68 nice action today ~ balamidas 01/06/17 12:38:03 PM
#1282   Boom hod !!!!! $VBIO simmons420 01/06/17 12:11:27 PM
#1281   interesting ! balamidas 01/05/17 12:44:05 PM
#1280   http://www.otcmarkets.com/stock/VBIO/news/Vitality-Biopharma-Comments-on-Recent- davidsson10 01/05/17 05:32:54 AM
#1278   If vbio could make $$5.00 then the big old Mt 01/03/17 12:46:24 PM
#1277   nice action ! balamidas 01/03/17 09:37:28 AM
#1276   There is no reason why this should not simmons420 01/03/17 09:36:01 AM
#1275   Nice continuation today off bullish engulfing last week. $Vbio simmons420 01/03/17 09:35:14 AM
#1274   that's the spirit looll balamidas 12/30/16 10:43:18 AM
#1273   Nice pick up $$$$ today. simmons420 12/30/16 10:40:32 AM
#1272   Looks like you were right $VBIO simmons420 12/30/16 10:40:02 AM
#1271   $VBIO is being an atm machine. simmons420 12/30/16 10:39:30 AM
#1270   Up and green today ~ balamidas 12/30/16 09:44:49 AM
#1269   This is not very encouraging for $VBIO. poohpooh 12/30/16 09:11:55 AM
#1268   When you get a minute check out ECGR, IgniteOTCBB 12/30/16 07:06:31 AM
#1267   VBIO should find support Friday ~ balamidas 12/29/16 11:44:53 PM
#1266   The SEC was screaming, "This means you $VBIO" poohpooh 12/29/16 06:01:47 PM
#1265   I also took a position today in the Motz 12/29/16 03:47:57 PM
#1264   Took a starter here today. mmjglassartist 12/29/16 03:39:34 PM
#1263   it hit a support range today at 1.95 balamidas 12/29/16 01:24:54 PM
#1262   LOOKS LIKE (SA) ACCOMPLISHED THEIR JOB OF PUMPING yaboy520 12/29/16 09:50:44 AM
#1261   dilution is 9 million shares. this thing minten 12/29/16 09:40:48 AM
#1260   Load at $1.50 Conman23 12/29/16 09:36:04 AM
#1259   no doubt! nasty close. dilution CBDpower 12/28/16 11:20:24 PM
#1258   looks like lower ground is gonna be tested balamidas 12/28/16 10:17:46 PM
#1257   weed is on the rise! lets see CBDpower 12/28/16 01:58:57 PM
#1256   lol no doubt! power of weed CBDpower 12/28/16 01:56:32 PM
#1255   huge news! surprised we havent rebounded with CBDpower 12/28/16 01:53:49 PM
#1254   $15 is my target, if they have 8 CBDpower 12/28/16 01:52:06 PM
#1253   you're a bit late. could work its way TrendTrade2016 12/28/16 01:45:48 PM
#1252   im looking for a $3 close today. CBDpower 12/28/16 01:43:42 PM
#1251   thats tiny! vbio could easily double or CBDpower 12/28/16 01:42:14 PM
#1250   all the weed plays are looking great! CBDpower 12/28/16 01:34:49 PM
#1249   chart was way above upper bolly and sky CBDpower 12/28/16 01:31:34 PM
#1248   very nice weed play here! tiny CBDpower 12/28/16 01:29:37 PM
#1247   holding this range well. wonder if it CBDpower 12/28/16 01:25:51 PM
#1246   the DEA checks whether the facility is OK. minten 12/28/16 12:06:50 PM
#1245   does dea think this company is a scam..? Mandofellow 12/28/16 11:40:46 AM
#1244   do you even know what VBIO does? minten 12/28/16 10:51:55 AM
#1243   good point ddt! balamidas 12/28/16 10:30:11 AM
#1242   None of these MJ OTCs are going to ddtburg 12/28/16 10:22:21 AM
#1241   very nice trades here this am $$$ VBIO :)) balamidas 12/28/16 10:11:29 AM
#1240   0.25 coming! ~MulaGreen~ 12/28/16 10:02:16 AM
#1239   or MM's are taking it down because the minten 12/28/16 09:59:40 AM
PostSubject